嘉应制药及董事长李能等因信息披露违规被警告并罚款

Group 1 - The company, Guangdong Jiaying Pharmaceutical Co., Ltd., was fined for failing to disclose related party transactions amounting to 21.999 million yuan, which represents 28.83% of its latest audited net assets [2] - The penalties include a fine of 1.5 million yuan for the company, 1.6 million yuan for the chairman Li Neng, 1 million yuan for the general manager You Yongping, and 800,000 yuan for the former financial director Shi Junping [2] - The company stated that this penalty does not trigger any major illegal delisting scenarios and that its production and operations remain normal [3] Group 2 - Jiaying Pharmaceutical was established on March 7, 2003, with a registered capital of 507.509848 million yuan, and is primarily engaged in the research, production, and sales of traditional Chinese medicine [3] - The company has six subsidiaries, including Guangdong Jiahui Financing Leasing Co., Ltd. and Hunan Jinsha Pharmaceutical Co., Ltd. [4] - The company's revenue for 2022, 2023, 2024, and the first three quarters of 2025 were 659 million yuan, 533 million yuan, 376 million yuan, and 293 million yuan, with year-on-year growth rates of 14.70%, -19.11%, -29.46%, and 13.03% respectively [4] - The net profit attributable to the parent company for the same periods were 43.9347 million yuan, 34.3202 million yuan, 20.6116 million yuan, and 21.7943 million yuan, with year-on-year growth rates of 2874.05%, -21.88%, -39.94%, and 658.50% respectively [4] - The company's asset-liability ratios for the same periods were 13.96%, 9.98%, 9.61%, and 8.48% [4] - The company has a total of 79 risk alerts, 487 surrounding risk alerts, 20 historical risk alerts, and 225 warning risk alerts according to Tianyancha [4]